Robert Cherny - Alterity Therapeutics Head Research
| PRNAF Stock | USD 0 0.00 0.00% |
Insider
Robert Cherny is Head Research of Alterity Therapeutics Limited
| Phone | 61 3 9349 4906 |
| Web | https://alteritytherapeutics.com |
Alterity Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2585) % which means that it has lost $0.2585 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3897) %, meaning that it generated substantial loss on money invested by shareholders. Alterity Therapeutics' management efficiency ratios could be used to measure how well Alterity Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Rebecca MD | Madrigal Pharmaceuticals | 72 | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
| Ian MBA | Jaguar Animal Health | 56 | |
| Thomas III | Ibio Inc | 57 | |
| Stephen Kilmer | Ibio Inc | N/A | |
| Dr Stapleton | Vaxart Inc | 53 | |
| Melissa Berquist | Ibio Inc | N/A | |
| Frank MD | Greenwich Lifesciences | 74 | |
| CPM EMBA | Genprex | 59 | |
| CPA CPA | Tonix Pharmaceuticals Holding | 50 | |
| James CFA | Novavax | 58 | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| Jean Davis | Northwest Biotherapeutics | 51 | |
| Carol Lizak | Jaguar Animal Health | 60 | |
| Nick DeLong | Ibio Inc | N/A | |
| Marianne Mancini | Viking Therapeutics | 59 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Vijay Tammara | Ocugen Inc | 64 | |
| David Innes | Northwest Biotherapeutics | N/A | |
| Robert Waltermire | Madrigal Pharmaceuticals | 60 | |
| Daniel MD | Tonix Pharmaceuticals Holding | N/A | |
Management Performance
| Return On Equity | -0.39 | |||
| Return On Asset | -0.26 |
Alterity Therapeutics Leadership Team
Elected by the shareholders, the Alterity Therapeutics' board of directors comprises two types of representatives: Alterity Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alterity. The board's role is to monitor Alterity Therapeutics' management team and ensure that shareholders' interests are well served. Alterity Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alterity Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BBus CA, Company Sec | ||
| Robert Cherny, Head Research | ||
| Kathryn Andrews, Chief Officer | ||
| BSc BSc, CoFounder Chairman | ||
| Steven Targum, Chief Advisor | ||
| David MD, Chief Officer | ||
| Rudolph Tanzi, Chief Board |
Alterity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Alterity Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.39 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.51) % | |||
| Operating Margin | (3.03) % | |||
| Current Valuation | (7.2 M) | |||
| Shares Outstanding | 2.41 B | |||
| Shares Owned By Insiders | 15.14 % | |||
| Shares Owned By Institutions | 0.33 % | |||
| Price To Earning | 0.88 X | |||
| Price To Book | 0.67 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Alterity Pink Sheet
Alterity Therapeutics financial ratios help investors to determine whether Alterity Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterity with respect to the benefits of owning Alterity Therapeutics security.